◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksN › NBIX

Neurocrine Biosciences Inc (NBIX) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · DATA UPDATED 2026-09-19

Neurocrine Biosciences Inc (NBIX) operates in the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry and is headquartered in San Diego, United States with about 2,500 employees. Its market capitalization is roughly $15 billion. In the fiscal year ended 2025-12-31, NBIX reported $2.9B in revenue and $479M in net income.

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.

Interactive charts & full statements → Open the NBIX valuation workbench →

NBIX Revenue & Earnings History — Annual Income Statement

Income statementTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-31
Total Revenue$3.4B$2.9B$2.4B$1.9B$1.5B$1.1B$1.0B$788M$451M$162M$15M$20M$0M$3M$53M$77M$34M$3M$4M$1M$39M
Gross Profit$3.3B$2.8B$2.3B$1.8B$1.5B$1.1B$1.0B$781M$446M$160M$15M$20M($14M)($11M)$42M$77M$34M$3M$4M$1M$39M
Gross Margin %98.0%98.2%98.6%97.9%98.4%98.7%99.0%99.1%98.9%99.2%100.0%100.0%-372.8%78.2%100.0%100.0%100.0%100.0%100.0%100.0%
Operating Income (EBIT)$789M$619M$570M$251M$249M$102M$163M$72M$37M($131M)($147M)($94M)($64M)($50M)$1M$34M($14M)($54M)($87M)($212M)($113M)
Operating Margin %23.4%21.6%24.2%13.3%16.7%9.0%15.6%9.2%8.2%-81.3%-982.5%-476.5%-1701.9%2.7%43.8%-41.0%-1817.5%-2196.2%-17340.0%-288.8%
Net Income$706M$479M$341M$250M$154M$90M$407M$37M$21M($143M)($141M)($89M)($61M)($46M)$5M$38M($8M)($51M)($89M)($207M)($107M)
Net Margin %20.9%16.7%14.5%13.2%10.4%7.9%38.9%4.7%4.7%-88.2%-940.6%-449.8%-1579.0%9.5%48.5%-23.8%-1728.3%-2229.3%-16936.2%-273.2%
EBITDA$667M$640M$416M$265M$138M$148M$86M$41M($121M)($140M)($88M)($64M)($49M)$2M$35M($12M)($48M)($74M)($203M)($103M)
Earnings Per Share (EPS)$6.84$4.67$3.29$2.47$1.56$0.92$4.16$0.39$0.22$-1.62$-1.63$-1.05$-0.81$-0.69$0.08$0.67$-0.15$-1.30$-2.30$-5.45$-2.84
Shares Outstanding (M)102M104M101M99M98M98M96M95M88M87M84M75M67M67M56M53M39M38M38M38M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NBIX Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Total Revenue$959M$814M$806M$795M$688M$573M$628M$622M$590M
Gross Profit$936M$801M$788M$781M$676M$563M$618M$614M$581M
Gross Margin %97.6%98.3%97.8%98.2%98.4%98.4%98.5%98.7%98.4%
Operating Income (EBIT)$153M$186M$211M$239M$146M$24M$142M$184M$145M
Operating Margin %16.0%22.8%26.2%30.1%21.2%4.1%22.6%29.5%24.6%
Net Income$144M$198M$154M$210M$108M$8M$103M$130M$65M
Net Margin %15.0%24.3%19.1%26.4%15.6%1.4%16.4%20.9%11.0%
EBITDA$254M$235M$300M$167M$31M$182M$191M$155M
Earnings Per Share (EPS)$1.39$1.91$1.50$2.04$1.06$0.08$1.00$1.24$0.63
Shares Outstanding (M)103M102M102M101M102M103M104M104M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NBIX Free Cash Flow History

Cash flowTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-31
Cash from Operations (CFO)$898M$783M$595M$390M$339M$256M$228M$147M$101M($94M)($106M)($38M)($47M)($30M)($35M)($1M)$50M($53M)($74M)($59M)($99M)
Capital Expenditures (CapEx)$32M$34M$38M$28M$16M$23M$11M$15M$25M$7M$4M$2M$2M$1M$1M$1M$0M$0M$1M$1M$3M
Free Cash Flow (FCF)$866M$749M$557M$362M$323M$233M$218M$132M$77M($101M)($110M)($40M)($49M)($30M)($36M)($1M)$50M($53M)($75M)($60M)($102M)
FCF Margin %25.7%26.2%23.7%19.2%21.7%20.6%20.8%16.8%17.0%-62.7%-735.3%-202.0%-1033.0%-68.2%-1.9%148.1%-1799.2%-1899.0%-4898.5%-261.1%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NBIX Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Cash from Operations (CFO)$136M$146M$388M$228M$102M$65M$242M$158M$65M
Capital Expenditures (CapEx)$8M$9M$2M$13M$12M$11M$7M$8M$12M
Free Cash Flow (FCF)$129M$137M$386M$214M$90M$54M$235M$150M$53M
FCF Margin %13.5%16.8%47.9%27.0%13.0%9.4%37.5%24.1%9.0%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NBIX Balance Sheet History

Balance sheet2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-31
Total Assets$5.4B$4.6B$3.7B$3.3B$2.4B$2.1B$1.7B$1.3B$993M$818M$365M$475M$243M$155M$196M$138M$144M$71M$118M$277M$390M
Cash & Cash Equivalents$332M$713M$233M$251M$263M$341M$187M$112M$142M$255M$83M$74M$31M$45M$64M$50M$54M$37M$68M$100M$81M
Total Liabilities$1.7B$1.4B$1.1B$1.0B$661M$698M$608M$669M$512M$445M$50M$50M$34M$34M$42M$78M$125M$67M$81M$158M$75M
Total Debt (Short + Long-Term)$0M$0M$170M$169M$352M$328M$818M$451M$408M$15M$12M$0M$0M$11M$8M$9M$4M$8M$110M$54M
Total Shareholders' Equity$3.7B$3.3B$2.6B$2.2B$1.7B$1.4B$1.1B$637M$481M$372M$315M$424M$209M$120M$154M$60M$19M$4M$37M$119M$315M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive NBIX viewer.

NBIX Metric Deep Dives

Other Companies in DRUG MANUFACTURERS - SPECIALTY & GENERIC

This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी

← NBISAll “N” companiesNBIZ →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.